Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uremic Pruritus
Conditions
Uremic Pruritus
Trial Timeline
Aug 10, 2020 → Oct 28, 2021
NCT ID
NCT04470154About Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04470154. Target conditions include Uremic Pruritus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04470154 | Phase 2 | Completed |
Competing Products
15 competing products in Uremic Pruritus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| CCX168 | Amgen | Phase 2 | 51 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 49 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine HCL ER | Trevi Therapeutics | Phase 1 | 28 |
| nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |